📣 VC round data is live. Check it out!

IDEXX Laboratories Valuation Multiples

Discover IDEXX Laboratories' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Siemens Healthineers, Wuxi AppTec, Agilent, Waters and more.

IDEXX Laboratories Overview

About IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.


Founded

1983

HQ

United States

Employees

11.0K

Website

idexx.com

Financials (LTM)

Revenue: $4B
EBITDA: $2B

EV

$44B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

IDEXX Laboratories Financials

IDEXX Laboratories reported last 12-month revenue of $4B and EBITDA of $2B.

In the same LTM period, IDEXX Laboratories generated $3B in gross profit, $2B in EBITDA, and $1B in net income.

Revenue (LTM)


IDEXX Laboratories P&L

In the most recent fiscal year, IDEXX Laboratories reported revenue of $4B and EBITDA of $2B.

IDEXX Laboratories is profitable as of last fiscal year, with gross margin of 62%, EBITDA margin of 35%, and net margin of 25%.

See analyst estimates for IDEXX Laboratories
LTMLast FY202320242025202620272028
Revenue$4B$4B$4B$4B$4B
Gross Profit$3B$3B$2B$2B$3B
Gross Margin62%62%60%61%62%
EBITDA$2B$2B$1B$1B$2B
EBITDA Margin35%35%33%33%35%
EBIT Margin32%32%30%29%32%
Net Profit$1B$1B$845M$888M$1B
Net Margin25%25%23%23%25%
Net Debt-$668M---

Financial data powered by Morningstar, Inc.

IDEXX Laboratories Stock Performance

IDEXX Laboratories has current market cap of $43B, and enterprise value of $44B.

Market Cap Evolution


IDEXX Laboratories' stock price is $550.82.

IDEXX Laboratories share price decreased by 2.3% in the last 30 days, and increased by 2.7% in the last year.

IDEXX Laboratories has an EPS (earnings per share) of $13.43.

See more trading valuation data for IDEXX Laboratories
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$44B$43B-2.8%-2.3%-2.0%2.7%$13.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

IDEXX Laboratories Valuation Multiples

IDEXX Laboratories trades at 9.9x EV/Revenue multiple, and 28.0x EV/EBITDA.

See NTM and 2027E valuation multiples for IDEXX Laboratories

EV / Revenue (LTM)


IDEXX Laboratories Financial Valuation Multiples

As of June 3, 2026, IDEXX Laboratories has market cap of $43B and EV of $44B.

IDEXX Laboratories has a P/E ratio of 39.3x.

LTMLast FY202320242025202620272028
EV/Revenue9.9x10.3x12.1x11.4x10.3x
EV/EBITDA28.0x29.4x36.4x34.9x29.4x
EV/EBIT31.0x32.6x40.4x39.3x32.6x
EV/Gross Profit16.0x16.7x20.3x18.6x16.7x
P/E39.3x41.0x51.4x48.9x41.0x
EV/FCF40.3x41.6x57.4x55.6x42.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified IDEXX Laboratories Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

IDEXX Laboratories Margins & Growth Rates

IDEXX Laboratories grew revenue by 9% and EBITDA by 12% in the last fiscal year.

In the most recent fiscal year, IDEXX Laboratories reported gross margin of 62%, EBITDA margin of 35%, and net margin of 25%.

See estimated margins and future growth rates for IDEXX Laboratories

IDEXX Laboratories Margins

Last FY202420252026202720282029
Gross Margin62%61%62%63%
EBITDA Margin35%33%35%36%
EBIT Margin32%29%32%32%
Net Margin25%23%25%25%
FCF Margin25%20%24%24%

IDEXX Laboratories Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%6%10%9%
Gross Profit Growth11%9%12%11%
EBITDA Growth12%4%19%12%
EBIT Growth12%3%21%12%
Net Profit Growth10%5%19%10%
FCF Growth8%3%31%10%

Data powered by FactSet, Inc. and Morningstar, Inc.

IDEXX Laboratories Operational KPIs

IDEXX Laboratories' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

IDEXX Laboratories' Rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IDEXX Laboratories' Rule of X is 59% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for IDEXX Laboratories
LTMLast FY202320242025202620272028
Rule of 4044%45%---
Bessemer Rule of X58%59%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue15%15%15%15%15%
G&A Expenses to Revenue10%9%9%11%9%
R&D Expenses to Revenue6%6%5%6%6%
Opex to Revenue-30%30%32%30%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

IDEXX Laboratories Competitors

IDEXX Laboratories competitors include Siemens Healthineers, Wuxi AppTec, Agilent, Waters, Edwards Lifesciences, Roper Technologies, Alcon, IQVIA, Veeva and DexCom.

Most IDEXX Laboratories public comparables operate across Medical Devices, Laboratory Services, Healthcare Software, BioTech, DeepTech, B2B SaaS, HealthTech and Vertical SaaS.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Siemens Healthineers1.6x1.6x7.9x7.9x
Wuxi AppTec5.9x5.6x9.7x11.3x
Agilent5.7x5.5x19.8x18.8x
Waters13.2x9.2x36.8x27.2x
Edwards Lifesciences7.8x7.5x26.2x24.4x
Roper Technologies5.6x5.4x13.9x13.6x
Alcon3.4x3.3x13.1x12.9x
IQVIA2.7x2.6x11.6x11.4x

This data is available for Pro users. Sign up to see all IDEXX Laboratories competitors and their valuation data.

Start Free Trial

Acquisitions by IDEXX Laboratories

IDEXX Laboratories has acquired 2 companies to date.

Last acquisition by IDEXX Laboratories was on August 22nd 2022. IDEXX Laboratories acquired TECTA-PDS for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by IDEXX Laboratories

TECTA-PDS
ezyVet
Description
TECTA-PDS is a Blacksburg, Virginia-based manufacturer of automated microbiological water monitoring systems approved by the US EPA. Its PDS 1000M analyzer detects coliforms and E. coli in drinking water within 15 hours using laser-based detection, deployed in utilities across North America and Europe.
ezyVet is a New Zealand-headquartered cloud-based practice management software for veterinary clinics worldwide. Founded in 2006 in Palmerston North, the platform handles appointments, inventory, billing, and patient records for over 5,000 practices across 80 countries. ezyVet integrates with diagnostic tools like Idexx and supports multi-location chains with real-time dashboards. The system features mobile apps for vets and clients, telemedicine modules, and compliance with standards in the US, UK, and Australia. It processes millions of transactions annually, emphasizing scalability from solo practices to corporate groups.
HQ CountryCanadaNew Zealand
HQ City
Toronto
Auckland
Deal Date22 Aug 20222 Jun 2021
Valuationundisclosed$157M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all IDEXX Laboratories acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About IDEXX Laboratories

When was IDEXX Laboratories founded?IDEXX Laboratories was founded in 1983.
Where is IDEXX Laboratories headquartered?IDEXX Laboratories is headquartered in United States.
How many employees does IDEXX Laboratories have?As of today, IDEXX Laboratories has over 11K employees.
Who is the CEO of IDEXX Laboratories?IDEXX Laboratories' CEO is Jonathan J. Mazelsky.
Is IDEXX Laboratories publicly listed?Yes, IDEXX Laboratories is a public company listed on Nasdaq.
What is the stock symbol of IDEXX Laboratories?IDEXX Laboratories trades under IDXX ticker.
When did IDEXX Laboratories go public?IDEXX Laboratories went public in 1991.
Who are competitors of IDEXX Laboratories?IDEXX Laboratories main competitors include Siemens Healthineers, Wuxi AppTec, Agilent, Waters, Edwards Lifesciences, Roper Technologies, Alcon, IQVIA, Veeva, DexCom.
What is the current market cap of IDEXX Laboratories?IDEXX Laboratories' current market cap is $43B.
What is the current revenue of IDEXX Laboratories?IDEXX Laboratories' last 12 months revenue is $4B.
What is the current revenue growth of IDEXX Laboratories?IDEXX Laboratories revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of IDEXX Laboratories?Current revenue multiple of IDEXX Laboratories is 9.9x.
What is the current EBITDA of IDEXX Laboratories?IDEXX Laboratories' last 12 months EBITDA is $2B.
What is IDEXX Laboratories' EBITDA margin?IDEXX Laboratories' last 12 months EBITDA margin is 35%.
What is the current EV/EBITDA multiple of IDEXX Laboratories?Current EBITDA multiple of IDEXX Laboratories is 28.0x.
What is the current FCF of IDEXX Laboratories?IDEXX Laboratories' last 12 months FCF is $1B.
What is IDEXX Laboratories' FCF margin?IDEXX Laboratories' last 12 months FCF margin is 25%.
What is the current EV/FCF multiple of IDEXX Laboratories?Current FCF multiple of IDEXX Laboratories is 40.3x.
How many companies IDEXX Laboratories has acquired to date?As of June 2026, IDEXX Laboratories has acquired 2 companies.
What was the largest acquisition by IDEXX Laboratories?$157M acquisition of ezyVet on 2nd June 2021 was the largest M&A IDEXX Laboratories has done to date.
In how many companies IDEXX Laboratories has invested to date?IDEXX Laboratories hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to IDEXX Laboratories

Lists including IDEXX Laboratories

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial